source
- Enveda reports promising Phase 1 data for oral drug that mimics exercise to preserve muscle during weight lossEnveda, a biotech based in Boulder, Colorado, announced Phase 1 results for its oral candidate ENV-308, a chemically engineered version of the metabolite lactate phenylalanine (lac-phe). The metabo…
- AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight lossAstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…BioPharma Dive · 2mo agoPositive readoutPositive